Further longitudinal studies should also examine the relationship between [18F]FDG‐PET and other biomarkers, such as dopamine transporter imaging with [123I]N‐ω‐fluoropropyl‐2β‐carbomethoxy‐3β‐(4‐iodophenyl)nortropane single‐photon emission computed tomography ([123I]FP‐CIT‐SPECT).23, 24 The latter is a well‐studied potential prodromal progression biomarker in alpha‐synucleinopathies. Here, SLC6A3 is linked to synucleinopathy.